9VQ Stock Overview
Belluscura plc develops and commercialize oxygen related medical device products.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Belluscura plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.081 |
| 52 Week High | UK£0.56 |
| 52 Week Low | UK£0.08 |
| Beta | 0.65 |
| 1 Month Change | -63.07% |
| 3 Month Change | -63.41% |
| 1 Year Change | -80.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9VQ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -6.4% | 2.1% | 0.5% |
| 1Y | -80.6% | -8.4% | 1.3% |
Return vs Industry: 9VQ underperformed the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: 9VQ underperformed the German Market which returned 1.3% over the past year.
Price Volatility
| 9VQ volatility | |
|---|---|
| 9VQ Average Weekly Movement | 18.1% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9VQ's share price has been volatile over the past 3 months.
Volatility Over Time: 9VQ's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 24 | Bob Rauker | www.belluscura.com |
Belluscura plc develops and commercialize oxygen related medical device products. The company offers X-PLOR, a modular portable oxygen concentrator. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.
Belluscura plc Fundamentals Summary
| 9VQ fundamental statistics | |
|---|---|
| Market cap | €14.91m |
| Earnings (TTM) | -€9.32m |
| Revenue (TTM) | €1.12m |
13.3x
P/S Ratio-1.6x
P/E RatioIs 9VQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9VQ income statement (TTM) | |
|---|---|
| Revenue | US$1.20m |
| Cost of Revenue | US$314.50k |
| Gross Profit | US$888.06k |
| Other Expenses | US$10.89m |
| Earnings | -US$10.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.061 |
| Gross Margin | 73.85% |
| Net Profit Margin | -831.70% |
| Debt/Equity Ratio | 0.4% |
How did 9VQ perform over the long term?
See historical performance and comparison